264 related articles for article (PubMed ID: 30651063)
1. Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study.
Cosentino ER; Landolfo M; Bentivenga C; Spinardi L; Esposti DD; Cicero AF; Miceli R; Bui V; Berardi E; Borghi C
BMC Cardiovasc Disord; 2019 Jan; 19(1):20. PubMed ID: 30651063
[TBL] [Abstract][Full Text] [Related]
2. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
3. Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease.
Inui N; Matsushima S; Kato S; Yasui H; Kono M; Fujisawa T; Enomoto N; Nakamura Y; Toyoshima M; Suda T
Int J Chron Obstruct Pulmon Dis; 2015; 10():1139-46. PubMed ID: 26124653
[TBL] [Abstract][Full Text] [Related]
4. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium
Beaulieu J; Jensen D; O'Donnell DE; Brouillard C; Tracey L; Vincent S; Nadreau É; Bernard E; Bernard S; Maltais F
Ther Adv Respir Dis; 2020; 14():1753466620939507. PubMed ID: 32663102
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
8. Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.
Singh MP
Int J Chron Obstruct Pulmon Dis; 2013; 8():613-9. PubMed ID: 24353411
[TBL] [Abstract][Full Text] [Related]
9. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Vogelmeier C; Zhong N; Humphries MJ; Mezzi K; Fogel R; Bader G; Patalano F; Banerji D
Int J Chron Obstruct Pulmon Dis; 2016; 11():3189-3197. PubMed ID: 28008244
[TBL] [Abstract][Full Text] [Related]
10. Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Banerji D; Fogel R; Patalano F
Drug Discov Today; 2018 Jan; 23(1):196-203. PubMed ID: 29079130
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Vogelmeier CF; Gaga M; Aalamian-Mattheis M; Greulich T; Marin JM; Castellani W; Ninane V; Lane S; Nunez X; Patalano F; Clemens A; Kostikas K;
Respir Res; 2017 Jul; 18(1):140. PubMed ID: 28720132
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
[TBL] [Abstract][Full Text] [Related]
15. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
Rossi A; Zanardi E; Poletti V; Cazzola M
Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
[TBL] [Abstract][Full Text] [Related]
16. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
Kardos P; Hagedorn-Peinz I
Int J Chron Obstruct Pulmon Dis; 2018; 13():69-77. PubMed ID: 29317812
[TBL] [Abstract][Full Text] [Related]
17. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study.
Blais CM; Davis BE; Cockcroft DW
Respir Res; 2017 Aug; 18(1):146. PubMed ID: 28768531
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
[TBL] [Abstract][Full Text] [Related]
19. Coexisting Heart Failure and Chronic Obstructive Pulmonary Disease: Report of Two Cases Treated with Indacaterol/Glycopyrronium.
Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Ricci Iamino I; Spinardi L; Magri G; Borghi C
Respiration; 2018; 95 Suppl 1():3-5. PubMed ID: 29705784
[TBL] [Abstract][Full Text] [Related]
20. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA; Banerji D; Chapman KR; Vestbo J; Roche N; Ayers RT; Thach C; Fogel R; Patalano F; Vogelmeier CF;
N Engl J Med; 2016 Jun; 374(23):2222-34. PubMed ID: 27181606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
